Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
- FDA grants pre-IND Type B meeting request
- Written responses expected by mid-November 2026
- Vectus to finalise meeting package with Cardinal Health
- VB0004 completed a Phase Ia study in healthy volunteers
- No clinical trial approval or development timetable disclosed
FDA Meeting Request Granted for VB0004
Vectus Biosystems Limited (ASX:VBS) has cleared an important regulatory gate for VB0004, with the US Food and Drug Administration granting a pre-Investigational New Drug Type B meeting request for the company’s proposed idiopathic pulmonary fibrosis development program.
The milestone gives Vectus a formal channel to seek written FDA feedback on its US plans. It is not an approval to begin a clinical trial, and the substance of the regulator’s guidance remains pending.
Written FDA Guidance Due in November
Vectus expects the FDA’s detailed written responses by mid-November 2026. Before then, the company will finalise and submit its meeting package in conjunction with Cardinal Health Regulatory Services, its US regulatory agent.
That feedback is expected to inform the next stages of VB0004’s clinical and regulatory development. The announcement does not disclose the proposed trial design, any additional non-clinical requirements, development costs or the timing of a future IND submission.
Phase Ia Data Supports Further Development
VB0004 is described as an oral VIP-mimetic and natriuretic peptide receptor C agonist being developed for IPF, a progressive lung disease. Vectus says its first Phase Ia study in healthy volunteers established a favourable safety and pharmacokinetic profile.
Those results provide the clinical foundation cited by the company for moving into the next phase of development, although the announcement supplies no efficacy data and does not indicate how the FDA will respond to the proposed program.
Regulatory Feedback Becomes the Next Catalyst
For Vectus, the November response is the immediate test of whether its intended US pathway is aligned with FDA expectations. The company is also developing antifibrotic assets targeting cardiovascular, renal and liver fibrosis, but VB0004 remains the lead program highlighted in this announcement.
The key question is what the written guidance requires before the company can advance toward a US clinical study, and whether Vectus has the resources to meet those requirements. Until the FDA responds, the regulatory progress is meaningful but still preparatory.
Bottom Line?
The FDA has opened the door to formal guidance, but the next value-defining step is the content of the November response rather than the meeting request itself.
Questions in the middle?
- What clinical design and additional non-clinical work will the FDA require for VB0004?
- When could Vectus submit an IND and begin a US clinical study?
- How will the company fund the next stage of development once the FDA guidance arrives?